192 related articles for article (PubMed ID: 27302413)
1. Structure of neprilysin in complex with the active metabolite of sacubitril.
Schiering N; D'Arcy A; Villard F; Ramage P; Logel C; Cumin F; Ksander GM; Wiesmann C; Karki RG; Mogi M
Sci Rep; 2016 Jun; 6():27909. PubMed ID: 27302413
[TBL] [Abstract][Full Text] [Related]
2. Disposition and metabolism of [(14)C] Sacubitril/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects.
Flarakos J; Du Y; Bedman T; Al-Share Q; Jordaan P; Chandra P; Albrecht D; Wang L; Gu H; Einolf HJ; Huskey SE; Mangold JB
Xenobiotica; 2016 Nov; 46(11):986-1000. PubMed ID: 26931777
[TBL] [Abstract][Full Text] [Related]
3. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
4. Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition.
Hanna I; Alexander N; Crouthamel MH; Davis J; Natrillo A; Tran P; Vapurcuyan A; Zhu B
Xenobiotica; 2018 Mar; 48(3):300-313. PubMed ID: 28281384
[TBL] [Abstract][Full Text] [Related]
5. The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey.
Schoenfeld HA; West T; Verghese PB; Holubasch M; Shenoy N; Kagan D; Buono C; Zhou W; DeCristofaro M; Douville J; Goodrich GG; Mansfield K; Saravanan C; Cumin F; Webb RL; Bateman RJ
Toxicol Appl Pharmacol; 2017 May; 323():53-65. PubMed ID: 28315356
[TBL] [Abstract][Full Text] [Related]
6. Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor.
Gan L; Langenickel T; Petruck J; Kode K; Rajman I; Chandra P; Zhou W; Rebello S; Sunkara G
J Clin Pharmacol; 2016 Jan; 56(1):78-86. PubMed ID: 26073563
[TBL] [Abstract][Full Text] [Related]
7. The angiotensin II type 1 receptor-neprilysin inhibitor LCZ696 blocked aldosterone synthesis in a human adrenocortical cell line.
Miura SI; Suematsu Y; Matsuo Y; Tomita S; Nakayama A; Goto M; Arimura T; Kuwano T; Yahiro E; Saku K
Hypertens Res; 2016 Nov; 39(11):758-763. PubMed ID: 27334058
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).
Gu J; Noe A; Chandra P; Al-Fayoumi S; Ligueros-Saylan M; Sarangapani R; Maahs S; Ksander G; Rigel DF; Jeng AY; Lin TH; Zheng W; Dole WP
J Clin Pharmacol; 2010 Apr; 50(4):401-14. PubMed ID: 19934029
[TBL] [Abstract][Full Text] [Related]
9. Radiosynthesis of the
Teyssier VR; Simard JM; Dornan MH; Tournoux F; DaSilva JN
J Labelled Comp Radiopharm; 2020 Feb; 63(2):65-71. PubMed ID: 31912556
[TBL] [Abstract][Full Text] [Related]
10. Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.
Vilela-Martin JF
Drug Des Devel Ther; 2016; 10():1627-39. PubMed ID: 27274196
[TBL] [Abstract][Full Text] [Related]
11. Structure-Guided Design of Substituted Biphenyl Butanoic Acid Derivatives as Neprilysin Inhibitors.
Kawanami T; Karki RG; Cody E; Liu Q; Liang G; Ksander GM; Rigel DF; Schiering N; Gong Y; Coppola GM; Iwaki Y; Sun R; Neubert A; Fan L; Ingles S; D'Arcy A; Villard F; Ramage P; Jeng AY; Leung-Chu J; Liu J; Beil M; Fu F; Chen W; Cumin F; Wiesmann C; Mogi M
ACS Med Chem Lett; 2020 Feb; 11(2):188-194. PubMed ID: 32071687
[TBL] [Abstract][Full Text] [Related]
12. Long-term neprilysin inhibition - implications for ARNIs.
Campbell DJ
Nat Rev Cardiol; 2017 Mar; 14(3):171-186. PubMed ID: 27974807
[TBL] [Abstract][Full Text] [Related]
13. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
Nougué H; Pezel T; Picard F; Sadoune M; Arrigo M; Beauvais F; Launay JM; Cohen-Solal A; Vodovar N; Logeart D
Eur J Heart Fail; 2019 May; 21(5):598-605. PubMed ID: 30520545
[TBL] [Abstract][Full Text] [Related]
14. Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor.
Ayalasomayajula SP; Langenickel TH; Jordaan P; Zhou W; Chandra P; Albrecht D; Pal P; Rajman I; Sunkara G
Eur J Clin Pharmacol; 2016 Sep; 72(9):1065-73. PubMed ID: 27230850
[TBL] [Abstract][Full Text] [Related]
15. Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon.
Oefner C; D'Arcy A; Hennig M; Winkler FK; Dale GE
J Mol Biol; 2000 Feb; 296(2):341-9. PubMed ID: 10669592
[TBL] [Abstract][Full Text] [Related]
16. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.
Ansara AJ; Kolanczyk DM; Koehler JM
J Clin Pharm Ther; 2016 Apr; 41(2):119-27. PubMed ID: 26992459
[TBL] [Abstract][Full Text] [Related]
17. Substituted α-mercaptoketones, new types of specific neprilysin inhibitors.
Poras H; Patouret R; Leiris S; Ouimet T; Fournié-Zaluski MC; Roques BP
Bioorg Med Chem Lett; 2017 Aug; 27(16):3883-3890. PubMed ID: 28676269
[TBL] [Abstract][Full Text] [Related]
18. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.
Jhund PS; McMurray JJ
Heart; 2016 Sep; 102(17):1342-7. PubMed ID: 27207980
[TBL] [Abstract][Full Text] [Related]
19. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Crystalline Valsartan/Sacubitril (LCZ696) Compared With Placebo and Combinations of Free Valsartan and Sacubitril in Patients With Systolic Hypertension: The RATIO Study.
Izzo JL; Zappe DH; Jia Y; Hafeez K; Zhang J
J Cardiovasc Pharmacol; 2017 Jun; 69(6):374-381. PubMed ID: 28338503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
